Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic

• Published in: Clinics (São Paulo, Brazil) Vol. 75; p. e2022
• Main Authors: Almeida, Madson Q., Mendonca, Berenice B.
• Format: Journal Article
• Language: English
• Published: Brazil Elsevier España, S.L.U 01.01.2020; Faculdade de Medicina / USP; Elsevier España
• Subjects: Adrenal Insufficiency; Adrenal Insufficiency - complications; Adrenal Insufficiency - drug therapy; Betacoronavirus; Coronavirus Infections - prevention & control; COVID-19; Glucocorticoid; Glucocorticoids - administration & dosage; Humans; Hydrocortisone - administration & dosage; Injections, Intravenous; MEDICINE, GENERAL & INTERNAL; Pandemics - prevention & control; Pneumonia, Viral - prevention & control; Review; Risk Factors; SARS-CoV-2; Severity of Illness Index; COVID-19; Adrenal Insufficiency; SARS-CoV-2; Glucocorticoid
• ISSN: 1807-5932; 1980-5322; 1980-5322
• DOI: 10.6061/clinics/2020/e2022

The coronavirus disease 2019 (COVID-19) is an emerging pandemic challenge. Acute respiratory distress syndrome (ARDS) in COVID-19 is characterized by a severe cytokine storm. Patients undergoing glucocorticoid (GC) replacement therapy for adrenal insufficiency (AI) represent a highly vulnerable group that could develop severe complications due to the SARS-CoV-2 infection. In this review, we highlight the strategies to avoid an adrenal crisis in patients with AI and COVID-19. Adrenal crisis is a medical emergency and an important cause of death. Once patients with AI present symptoms of COVID-19, the dose of GC replacement therapy should be immediately doubled. In the presence of any emergency warning signs or inability to administer oral GC doses, we recommend that patients should immediately seek Emergency services to evaluate COVID-19 symptoms and receive 100 mg hydrocortisone by intravenous injection, followed by 50 mg hydrocortisone intravenously every 6 h or 200 mg/day by continuous intravenous infusion.